IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
|
|
- Marian Griffin
- 7 years ago
- Views:
Transcription
1 IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1
2 This brochure is a supplement to the healthcare provider s patient information on TYSABRI. IF YOU ARE RECEIVING TYSABRI This brochure is for people who have MS and whose doctor has prescribed the drug TYSABRI (natalizumab). You will find more information about TYSABRI, how the drug works, what effects you can expect, and any side effects. It also contains a brief background about the disease, what happens in your body and how it can affect you. Do not hesitate to contact your doctor or MS nurse if there is anything you wonder about, or need an answer to. Please read the package leaflet that is enclosed with TYSABRI before you start your treatment. This medicinal product is subject to additional monitoring. The black triangle is intended to be used in all EU member states to identify those medicines that are under additional monitoring, which means that the medicine is monitored more closely than other medicines. The black triangle makes it possible to quickly identify which medicines are under additional monitoring. Patients and healthcare personnel in particular are encouraged to report all suspected side effects of a medicine that is marked with the black triangle so that new information can be quickly evaluated. More information is available on 2
3 CONTENTS Facts about MS... 4 How TYSABRI acts... 7 Facts about the treatment... 9 Questions and answers Other information Terminology
4 FACTS ABOUT MS In Sweden about 18,000 people have multiple sclerosis, MS, and about 1,000 people become ill every year. MS is a neurological disease that affects the central nervous system (brain and spinal cord). The central nervous system can be described as the body's "computer". Nerve cells in the central nervous system receive and send out large amounts of information through the nerve fibres or "axons". The nerve fibres join the nerve cells together in an enormous network. The information is passed between the nerve cells as weak electrical impulses along the nerve fibres. The nerve fibres are surrounded by a fatty layer called myelin. This has an insulating effect so that the electrical signals travel quickly and efficiently. Healthy nerve fibre: Nerve cells send information through nerve fibres as electrical signals to other cells. The nerve fibres are surrounded by myelin, a fatty layer that acts as insulation and makes it easier for the electrical signals to travel. Damaged nerve fibre: The myelin has broken down making it difficult for the signals to travel between the nerve cells. 4
5 In MS, small inflammations occur in the brain or spinal cord. These damage the myelin causing it to break down. This makes it more difficult for the electrical signals to move through the affected area. The brain's ability to communicate effectively with the various parts of the body is affected. This makes it more difficult for the brain to control the nerves for motor function (movement) or to process sensory input. Most people with MS have relapses. This means that they have periods with symptoms due to new damage followed by better periods with weaker or no symptoms at all. The inflammation in MS can occur in different parts of the central nervous system. This means many bodily functions can be affected and the symptoms can vary from relapse to relapse and from person to person. Cerebrum Cerebellum Brain stem Spinal cord When the inflammation in the central nervous system has subsided, the nervous system can repair itself and rebuild the myelin around the nerve fibres. Occasionally the damage persists. In the long term, this persistent damage in the central nervous system increases and can cause increasing impairment of function. It is therefore important when choosing the treatment for MS to weigh up the advantages and risks of the treatment against the risks associated with the disease itself. 5
6 In time treatment At the beginning in relapsing-remitting MS there is often complete recovery after a relapse. The brain's repair cells build up new myelin around the nerve fibres. But new inflammations can lower the possibility for recovery. Once the myelin has broken down, the nerve fibre itself can be attacked and destroyed. Damage that occurs as a result of broken down nerve fibres or dead nerve cells can become permanent. This is why it is important to check as early as possible how active your disease is before damage occurs that the body cannot repair. If you are an adult with highly active relapsing-remitting MS you can be treated with TYSABRI. This means: Continued disease activity in spite of treatment with other disease-modifying drugs or High disease activity when the disease first appeared. 6
7 FACTS ABOUT TYSABRI How TYSABRI acts In MS, immune cells pass from the blood stream into the central nervous system. For some unknown reason, the immune cells have become programmed to attack the myelin, the insulating layer around the nerve fibres. TYSABRI is an antibody that affects the immune system and thus MS. TYSABRI prevents the cells that cause the inflammation in MS from entering the central nervous system by attaching to the immune cells' "keys". This means that the "keys" do not fit the "keyhole" in the central nervous system. This reduces the risk of new nerve damage. Nerve fibre with myelin Blood stream The immune cells 7
8 WHAT YOU CAN EXPECT FROM THE TREATMENT The best way to study and demonstrate the effects of a drug is to conduct so-called clinical studies. Researchers study how the disease develops in patients who receive the drug compared with a control group who receive a placebo (a drug with no effect). In clinical studies, TYSABRI almost halved the rate at which function impairment developed in MS, and it also reduced the number of MS relapses by about two-thirds. How will I know whether TYSABRI has an effect? When you are treated with TYSABRI you are regularly monitored for any effect. All relapses are noted, and any changes in physical and cognitive functions (capacity to move and think) are monitored. If you experience that your disease does not stabilise when treated with TYSABRI, you should discuss with your doctor whether this is the right treatment for you. If you are treated with TYSABRI you are followed up regularly for treatment effects 8
9 FACTS ABOUT THE TREATMENT One infusion every four weeks TYSABRI is administered as an intravenous infusion, this is a drip into a blood vessel in the arm. The drip is administered in the hospital Reception or on a Day Ward every fourth week by healthcare personnel and takes about an hour. In connection with the infusion you are checked for any allergic reactions; but these are uncommon. Attending the hospital every four weeks can offer additional security. These regular visits mean it will also be easy for healthcare personnel and your doctor to monitor the effects of your treatment. Patient information card You will be given a patient card which contains important information on TYSABRI. Show the card to all doctors and other healthcare personnel involved in your treatment. Show the patient card to your partner and family too, so that they are familiar with the treatment with TYSABRI and what they should be aware of. PATI INFOENT RMA TION CARD FOURTH EVERY WEEK 9
10 Side effects Most medicines give some side effects and that applies to TYSABRI as well. Most of the side effects with TYSABRI are mild and soon disappear. A small number of patients react with hypersensitivity associated with the infusion. The reaction normally occurs within a few hours and may mean that you need to stay behind for observation after the infusion. Other common side effects include urinary tract infections, sore throats and runny or blocked nose, shaking, itchy rashes (urticaria), headache, dizziness, nausea, vomiting, joint pain, fever and tiredness. Talk to your doctor if you experience any side effects. The patient information leaflet enclosed with TYSABRI contains more information on the side effects. PML an uncommon but serious infection In rare cases, treatment with TYSABRI has resulted in PML, progressive multifocal leukoencephalopathy. PML is an infection in the brain that can give serious consequences, including damage to the central nervous system in people who are affected. The infection is caused by a virus called the JC virus. About half the population carry this virus without it causing them any problems or disease. If you are treated with TYSABRI and carry the JC virus, there is a certain risk that you could develop PML. Carrying the virus does not mean that you will get PML; this is just one of three known risk factors The known risk factors are: Being a carrier of the JC virus, which is necessary for development of PML. If you are a carrier of the JC virus your risk is also affected by: How long the treatment is continued. Previous treatment with an immunosuppressive drug, which means a drug that inhibits the body s defence systems. 10
11 TYSABRI was approved in In June 2015 about 142,000 MS patients around the world had been treated with TYSABRI. Individual assessment of the treatment and follow-up A simple blood test is used to determine whether there are antibodies to the JC virus in the blood. If antibodies are present, the test result will be positive ; this means the virus is present in the body. If you do not have antibodies to the JC virus the test result is negative. This test helps you and your doctor assess the risk of PML and helps to ensure that you get the best treatment and follow-up. Important to be alert The symptoms with PML are similar to the symptoms with MS. It is therefore important that if you are receiving TYSABRI you are alert, and immediately contact your doctor if you feel your MS is getting worse or if you experience new symptoms. This will enable us to exclude early that it is PML. Tell your close family about the treatment so that they can help you notice any changes or worsening of your condition. 11
12 QUESTIONS AND ANSWERS What happens if I am hypersensitive to TYSABRI? If you are found to be hypersensitive to TYSABRI you will most probably not be allowed to continue the treatment with TYSABRI What happens if I become pregnant? Tell your doctor if you are pregnant, believe you are pregnant or are planning to become pregnant. You must not use TYSABRI if you are pregnant unless you have first discussed this with your doctor. Many people experience a significant improvement in their MS while they are pregnant. However, a few months after giving birth there is an increased risk of a relapse. Can I breastfeed? You must not breastfeed if you are being treated with TYSABRI. Discuss with your doctor when deciding whether to breastfeed or receive TYSABRI. Can I drive a car? TYSABRI is not expected to affect your ability to drive a car or use machinery. Talk to your doctor if you are uncertain. Can I take other medicines? Tell your doctor if you take or have recently taken other medicines. This also applies to herbal products and over-the-counter medicines. Can I stop my treatment temporarily? After each infusion TYSABRI disappears slowly from the body. TYSABRI is therefore given every fourth week to ensure that there is sufficient medicine in the blood. If the time between infusions is longer than four weeks, the effect of the treatment may be reduced and the activity of your MS could increase. Any temporary pause in your treatment, for example in connection with pregnancy, must be discussed with your doctor. 12
13 OTHER INFORMATION Talk to your doctor or nurse if you have any questions about your disease or treatment. They have the best overview of your treatment and situation. provides more information and reports on MS. More information on TYSABRI: read the patient information leaflet on FASS.se. See also 13
14 QUESTIONS I MUST REMEMBER TO ASK THE DOCTOR 14
15 TERMINOLOGY Antibody Proteins that are used by the body s immune system to detect and identify foreign substances such as viruses or bacteria. If the body forms antibodies against a given substance this is a sign that the substance is present in the body. Autoimmune disease A disease in which the immune system attacks the body s own tissues. Examples include MS and rheumatoid arthritis. Axon Nerve fibre that links nerve cells together with other cells Central nervous system (CNS) Comprises the brain and spinal cord and acts as the body s control and communication centre. Cognition The capacity to think, plan and remember. Disease-modifying drug A medicine that slows the progression of a chronic disease. TYSABRI is an example of a disease-modifying drug. Function impairment Reduced ability to function physically or mentally. Immune system The collective name for the body s complex defence mechanisms against infections. Immunosuppressive drug Medicine that is used to inhibit and slow the body s immune system so that it does not reject foreign substances in the body, for example after a transplant. Inflammation Reaction to damage to a tissue. Infusion Supply of a medicine, for example through a drip into a blood vessel in the arm. JC virus, JCV A virus that is carried by about half the population without it causing disease. When treated with TYSABRI, the JC virus has been shown to give an increased risk of developing PML. Multiple sclerosis Means many scars, and denotes the scars in the nervous tissue after the inflammatory reaction has ceased. Myelin The fatty sheath that protects the nerve fibres and makes it possible for the electrical signals to travel through the nerve fibres. Damage to the myelin makes it difficult for the signals to travel through the fibres. Natalizumab The active substance in TYSABRI. Natalizumab is an antibody that is similar to the antibodies produced by the body. Nerve Expressed simply, it is a type of cell that sends signals from various parts of the body to the brain and from the brain out to the body. Nerve fibre Another name for an axon, a projection on a nerve cell through which signals are sent to other cells. Patient information leaflet The printed information that is enclosed with a medicine. This information is also available on FASS.se. Placebo A medicine that does not contain any active ingredients. Is used for comparison in medical trials when studying the effect of a given medicine. PML Progressive multifocal leukoencephalopathy is a rare and serious virus infection in the brain. Quality of life The term quality of life is used to measure the subjective feeling of having a good life. This can be studied over time using various methods. Relapse A disease episode with a period of worsening due to new damage to the myelin. Side effect An unexpected or unintended effect of a medicine. 15
16 The information in this brochure is intended to form part of the information on TYSABRI provided for the patient by the treating doctor. The text is based on the patient information leaflet and the Summary of Product Characteristics for TYSABRI. See also TY-SWE-0191 / November 2015 TYSABRI (natalizumab), 300 mg concentrate for solution for infusion. Read the patient information leaflet before you start treatment with TYSABRIL. This drug is under additional monitoring. t Indications: Tysabri is intended for patients with highly active relapsing-remitting multiple sclerosis in spite of treatment with beta-interferon or glatiramer acetate; or patients with rapidly developing severe relapsing-remitting multiple sclerosis. Posology and method of administration: Tysabri is administered as a 300 mg infusion every four weeks under monitoring by healthcare personnel. Special warnings and precautions for use: Treatment with TYSABRI has been associated with an increased risk for PML, progressive multifocal leukoencephalopathy. Before start of treatment with Tysabri results of magnetic resonance imaging (MRI) performed within the last three months must be available for reference. The patients must be regularly checked for new or worsened neurological symptoms or status findings that could indicate PML Contraindications: Hypersensitivity to natalizumab or any of the excipients listed in the contents. Progressive multifocal leukoencephalopathy (PML). Patients with an increased risk for opportunistic infections, including patients with a compromised immune system. Combination with beta-interferons or glatiramer acetate. Known active cancers with the exception of patients with dermal basal cell cancer. Children and adolescents less than 18 years of age. Based on the Summary of Product Characteristics: 09/ Biogen Sweden AB Kanalvägen 12, Floor 7, Upplands Väsby Tel Fax
Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationRituximab. Drug information Rituximab. This leaflet provides information on rituximab and will answer any questions you have about the treatment.
Drug information Rituximab Rituximab This leaflet provides information on rituximab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets entirely
More informationThe MS Disease- Modifying Drugs. Gener al information
The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationMS Treatments Gilenya
1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,
More informationAn introduction to modern MS treatments
BETAFERON is a Prescription Medicine. Use strictly as directed. Consult your pharmacist or other health professional in case of side effects. BETAFERON is reimbursed for some patients. See your neurologist
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationPackage leaflet: Information for the patient. TYSABRI 300 mg concentrate for solution for infusion natalizumab
Package leaflet: Information for the patient TYSABRI 300 mg concentrate for solution for infusion natalizumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationManaging the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationswine flu vaccination:
swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationCBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area
April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the
More informationStepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationTAKING THE NEXT STEP
FOR ADULTS WITH MS TAKING THE NEXT STEP AMPYRA TREATMENT GUIDE walking better matters See the Patient Medication Guide below. About AMPYRA (dalfampridine) Extended release tablets How is AMPYRA different?
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationPackage leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab
Package leaflet: Information for the patient Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationDisease modifying drug therapy
Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about
More informationMEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationQUESTIONS TO ASK MY DOCTOR
Be a part of the treatment decision by asking questions QUESTIONS TO ASK MY DOCTOR FOR PATIENTS WITH ADVANCED STOMACH OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER CYRAMZA (ramucirumab) is used alone or in
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationAUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
More informationPatient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)
Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationBlood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.
Blood Transfusion Introduction Blood transfusions can save lives. Every second, someone in the world needs a blood transfusion. Blood transfusions can replace the blood lost from a serious injury or surgery.
More informationMultiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
More informationInfl ectra for rheumatoid arthritis
Infl ectra for rheumatoid arthritis Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationTHE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL
THE 7:16 WAS ON TIME BUT MY LEGS WERE BEHIND SCHEDULE THAT S WHEN I ASKED FOR THE WALKING PILL See page 12 for FREE* TRIAL OFFER *Limitations and restrictions apply. Actor portrayal AMPYRA (dalfampridine)
More informationDisease modifying drug therapy
Disease modifying drug therapy New edition for 2014-15 We hope you find the information in this book helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationMitoxantrone. For multiple sclerosis. InfoNEURO INFORMATION FOR PATIENTS. Montreal Neurological Hospital
i InfoNEURO Montreal Neurological Hospital INFORMATION FOR PATIENTS Mitoxantrone For multiple sclerosis Centre universitaire de santé McGill McGill University Health Centre Collaborators: D. Lowden Clinical
More informationMEDICATION GUIDE STELARA
MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase
More informationINFUSE Bone Graft (rhbmp-2/acs)
1 INFUSE Bone Graft (rhbmp-2/acs) For patients who need more bone to place dental implants Enjoy living with INFUSE Bone Graft. www.medtronic.com Medtronic Spinal and Biologics Business Worldwide Headquarters
More informationCAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationMULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author
MULTIPLE SCLEROSIS Mary Beth Rensberger, RN, BSN, MPH Author All rights reserved. Purchasers of this module are permitted to reproduce the forms contained herein for their individual internal use only.
More informationMultiple sclerosis. Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people. What is Multiple Sclerosis?
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people Multiple sclerosis When young people are told that they have a diagnosis of Multiple Sclerosis (MS) they usually
More informationAMPYRA (dalfampridine) Important Safety Information
NEWS RELEASE Acorda to Present New rhigm22 and AMPYRA (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 10/7/2015 ARDSLEY, N.Y.--(BUSINESS
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationBlood Transfusion. Red Blood Cells White Blood Cells Platelets
Blood Transfusion Introduction Blood transfusions are very common. Each year, almost 5 million Americans need a blood transfusion. Blood transfusions are given to replace blood lost during surgery or serious
More informationTYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
More informationFAQs on Influenza A (H1N1-2009) Vaccine
FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale
More informationWhat You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide
For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions
More informationEMA and Progressive Multifocal Leukoencephalopathy.
EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of
More informationLeflunomide Leflunomide
Drug information Leflunomide Leflunomide This leaflet provides information on leflunomide and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationSevere rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More information2 What you need to know before you have Ampiclox
Reason for update: GDS 14 & QRD Updates Response to questions for variation update section 4.1 of SPC MHRA Submission Date: 6 November 2014 MHRA Approval Date: Text Date: October 2014 Text Issue and Draft
More informationTreatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )
Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity
More informationSummary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
More informationDisease modifying drug therapy. what you need to know
Disease modifying drug therapy what you need to know Contact information Neurologist s name: Neurologist s secretary: Telephone number: MS specialist nurse: Telephone number: Manufacturer helpline number:
More informationThe MS Disease- Modifying Medications GENERAL INFORMATION
The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationSHINGLES (Herpes zoster infection)
SHINGLES (Herpes zoster infection) What are the aims of this leaflet? This leaflet has been written to help you understand more about shingles. It will tell you what it is, what causes it, what can be
More informationA neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationInformation About Medicines for Multiple Sclerosis
Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationBOTOX Treatment. for Chronic Migraine. Information for patients and their families. Botulinum Toxin Type A
BOTOX Treatment Botulinum Toxin Type A for Chronic Migraine Information for patients and their families. Is Chronic Migraine the same as Migraine? Chronic Migraine is similar to migraine as sufferers experience
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationUse of oral steroids in Multiple Sclerosis
Use of oral steroids in Multiple Sclerosis Information for patients and carers Neurology Department Aberdeen Royal Infirmary What are steroids? The steroids used to treat Multiple Sclerosis (MS) relapses
More informationBayer Receives FDA Approval for BETACONNECT First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
News Release Intended for U.S. Media Only Bayer Receives FDA Approval for BETACONNECT First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Whippany, N.J., September
More informationTuberculosis: FAQs. What is the difference between latent TB infection and TB disease?
Tuberculosis: FAQs What is TB disease? Tuberculosis (TB) is a disease caused by bacteria (germs) that are spread from person to person through the air. TB usually affects the lungs, but it can also affect
More informationLiving with MS. Multiple Sclerosis Society of Canada Call toll-free in Canada: 1-800-268-7582 Email: info@mssociety.ca Web site: www.mssociety.
Living with MS Multiple sclerosis is believed to be an immune-mediated disease, in which cells of a person s immune system attack the protective covering (called myelin) around nerve fibres in the central
More informationI B2.4. Design of the patient information leaflet for VariQuin
(English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to
More informationPATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN
PATIENT INFORMATION LEAFLET CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationINFUSE Bone Graft. Patient Information Brochure
INFUSE Bone Graft Patient Information Brochure This Patient Guide is designed to help you decide whether or not to have surgery using INFUSE Bone Graft to treat your broken tibia (lower leg). There are
More informationAbout MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?
An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? RA is the second most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most often appears between
More informationMEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets
MEDICATION GUIDE (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets Read this Medication Guide carefully before you start taking and each time you get a refill. There may
More informationIn non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:
EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human
More informationIntravenous Immunoglobulin in Neurological disorders
Intravenous Immunoglobulin in Neurological disorders Exceptional healthcare, personally delivered What is Intravenous Immunoglobulin (IVIg)? Intravenous immunoglobulin (IVIg) is a blood product that combines
More informationInformation about medicines for multiple sclerosis
Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationPATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr CYRAMZA ramucirumab Read this carefully before you receive CYRAMZA (pronounced "si ram - ze"). This leaflet is a
More informationMultiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationThe flu vaccination WINTER 2016/17. Who should have it and why. Flu mmunisation 2016/17
The flu vaccination WINTER 2016/17 Who should have it and why Flu mmunisation 2016/17 The flu vaccination 1 Winter 2016/17 Helping to protect everyone, every winter This leaflet explains how you can help
More informationHaving denervation of the renal arteries for treatment of high blood pressure
Having denervation of the renal arteries for treatment of high blood pressure The aim of this information sheet is to help answer some of the questions you may have about having denervation of the renal
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationREAD THIS LEAFLET VERY CAREFULLY, AND KEEP IT IN A SAFE PLACE. FLU IS SPREADING IN IRELAND, AND THIS INFORMATION IS IMPORTANT FOR YOU AND YOUR FAMILY.
READ THIS LEAFLET VERY CAREFULLY, AND KEEP IT IN A SAFE PLACE. FLU IS SPREADING IN IRELAND, AND THIS INFORMATION IS IMPORTANT FOR YOU AND YOUR FAMILY. Information and medical advice for the public on Pandemic
More informationBone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer
Bone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer A Review of the Research for Parents and Caregivers Is This Information Right
More informationIntravenous Methyl Prednisolone in Multiple Sclerosis
Intravenous Methyl Prednisolone in Multiple Sclerosis Exceptional healthcare, personally delivered Relapse management in multiple sclerosis Relapses in multiple sclerosis (MS) are common and caused by
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More information